Tag Archives: prasugrel

Doctor con tabletas de aspirinas

Prasugrel vs. Ticagrelor in Diabetics with Heart Disease

Prasugrel vs. Ticagrelor in Diabetics with Heart Disease

Diabetic patients are increased risk of thrombotic events, which is why an effective antiplatelet therapy is crucial for these patients. Both prasugrel and ticagrelor have shown to reduce thrombotic complications further than clopidogrel.   Subgroup analyzes of the most important studies testing prasugrel and ticagrelor vs. clopidogrel have shown that diabetic patients receiving the new

Prasugrel vs. Ticagrelor in Primary Angioplasty

The choice of prasugrel or ticagrelor for patients with acute myocardial infarction undergoing primary angioplasty makes no difference, at least in the short term.   This study was terminated prematurely and thus lost statistical power, which means that any interpretation of the lack of difference between the two antiplatelet drugs must take into account such

STEMI: Best P2Y12 inhibitor according to network meta-analysis

Original Title: Optimal P2Y12 inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a network meta-analysis. Reference: Rafique AM et al. J Am Coll Cardiol Intv 2016;9:1036–46.   Courtesy of Dr. Alejandro Lakowsky.     Researchers drew up a network meta-analysis incorporating 37 trials with more than 88,000 patients undergoing ST elevation

Effects of switching from prasugrel to ticagrelor in patients with ACS

Original Title: Pharmacodynamic Effects of Switching from Prasugrel to Ticagrelor Results of the Prospective, Randomized SWAP-3 Study Reference: J Am Coll Cardiol Intv. 2016;() Epub ahead of print. Courtesy of Dr. Agustín Vecchia. At present, the pharmacodynamic effects of switching from prasugrel to ticagrelor in patients under dual APT remain unknown. The present prospective, randomized,

¿Desescalar la doble antiagregación es el nuevo paradigma?

Optimal Duration of Dual Antiplatelet Therapy: New ACC-AHA Guidelines

Original Title: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Reference: Levine GN et al. Circulation. 2016 Mar 29. [Epub ahead of print]. Courtesy of Dr. Alejandro Lakowsky.  The new ACC-AHAGuidelines on the optimal duration of dual antiplatelet therapy(DAPT) in patients with coronary artery disease have just been

Aspirina o clopidogrel post TAVI: Guías y estudios llenos de contradicciones

Different Thienopyridine Loading Strategies to Get the Fastest Effect

Original Title: Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention. The Excelsior LOAD Trial. Reference: Willibald Hochholzer et al. J Am Coll Cardiol Intv. 2016, online before print.   This study assesses how to provide a more rapid antiaggregant effect. It compares the effect of a prasugrel load vs. a 600

Triple Antithrombotic Scheme in AMI Patients undergoing PCI

Original Title: Outcomes of Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy, a Comparison of Clopidogrel vs. Prasugrel from the TRANSLATE-ACS Study. Reference: Jackson L.R. et al. JACC Cardiovasc Interv. 2015 Dec 21;8(14):1880-9. Courtesy of Dr Agustín Vecchia. In these last years, new and more powerful antiaggregants have

Prasugrel in the Treatment of Clopidogrel Nonresponders Undergoing PCI

Original Title: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention (RECLOSE-3 study). Reference: Valenti R, et al. JACC Cardiovasc Interv. 2015 Oct;8(12):1563-70. Clopidogrel Nonresponders have higher risk of adverse events (cardiovascular death and stent thrombosis) compared to responders. Studies published so far have failed to demonstrate the use of platelet function tests in ACS patient

Meta-analysis of prolonged DAT after DES

Extending the antiaggregation therapy over a year reduces adverse events in patients with a history of AMI, according to this meta-analysis simultaneously published in the European Heart Journal. They analyzed data from 33.435 patients (mean age 64; 24% women) with a history of infarction included in one of the following clinical trials: CHARISMA, PRODIGY, ARCTIC-Interruption,

Top